3-(8-fluoro-4-quinolinyl)-2-methyl-5-(trifluoromethyl)-1H-indole-1-acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(8-fluoro-4-quinolinyl)-2-methyl-5-(trifluoromethyl)-1H-indole-1-acetic acid
• 英文别名: 2-[3-(8-fluoroquinolin-4-yl)-2-methyl-5-(trifluoromethyl)indol-1-yl]acetic Acid
• 化学式: C₂₁H₁₄F₄N₂O₂
• 分子量: 402.348
• InChiKey: XWRFXEGUGBWRKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] NOVEL SUBSTITUTED INDOLES<br/>[FR] NOUVEAUX INDOLES SUBSTITUES
  申请人：ASTRAZENECA AB

  公开号：WO2003101981A1

  公开（公告）日：2003-12-11

  The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.

  本发明涉及式(I)的取代吲哚化合物，可用作治疗呼吸系统疾病的药物化合物。
• Novel substituted indoles
  申请人：Birkinshaw Timothy

  公开号：US20050222201A1

  公开（公告）日：2005-10-06

  The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.

  本发明涉及公式(I)的取代吲哚，作为用于治疗呼吸系统疾病的药物化合物。
• Novel Substituted Indoles
  申请人：Birkinshaw Timothy

  公开号：US20100210685A1

  公开（公告）日：2010-08-19

  The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.

  本发明涉及式(I)的取代吲哚，作为治疗呼吸系统疾病的药物化合物。
• NOVEL SUBSTITUTED INDOLES
  申请人：AstraZeneca AB

  公开号：EP1549634A1

  公开（公告）日：2005-07-06
• Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
  申请人：Atopix Therapeutics Limited

  公开号：US20140328861A1

  公开（公告）日：2014-11-06

  Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof.